MedTrace Logo

CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM

NCT01761643 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 398

Last updated 2020-06-30

Study results available
· View outcomes & findings →

Summary

CCTG 595 is a controlled, open-label, two-arm, randomized (1:1) clinical demonstration project to determine if the use of a text-message based adherence intervention (iTAB) improves retention and adherence to PrEP compared to standard of care (SoC) PrEP delivery.

Conditions

  • Patient Adherence
  • HIV Seronegativity

Interventions

DEVICE

SoC + iTab

Text messaging reminders to improve adherence to PrEP

Sponsors & Collaborators

Principal Investigators

  • Sheldon Morris, MD, MPH · CCTG, UCSD AVRC

  • David Moore, PhD · CCTG, UCSD HNRP

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-12-19
Primary Completion
2018-06-13
Completion
2018-07-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01761643 on ClinicalTrials.gov